Ribostamycin

Ribostamycin (Vistamycin) is a broad-spectrum aminoglycoside antibiotic. Ribostamycin is effective against Gram-Negative and Gram-Positive bacterial infection. Ribostamycin also inhibits the chaperone activity of PDI[1][2].

Product Specifications

CAS Number

[25546-65-0]

Product Name Alternative

Vistamycin; SF-733

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Antibiotic; Bacterial; PDI

Type

Natural Products

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ribostamycin.html

Purity

99.89

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

NC[C@H]([C@H]([C@@H]([C@H]1N)O)O)O[C@@H]1O[C@H]([C@H](C[C@H]([C@@H]2O)N)N)[C@@H]2O[C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO

Molecular Formula

C17H34N4O10

Molecular Weight

454.47

Precautions

H315, H319, H335

References & Citations

[1]Zheng T, et al. Linear self-assembly formation between gold nanoparticles and aminoglycoside antibiotics. Colloids Surf B Biointerfaces. 2018 Apr 1;164:185-191. |[2]Hunfeld KP, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001 Mar;17 (3) :203-8.|[3]Horibe T, et al. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289 (5) :967-72. |[4]Kong J, et al. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol. 2020 Jul 29;11:1718. |[5]Kitasato I, et al. Comparative nephrotoxicity of ribostamycin and gentamicin in rats evaluated by urinalysis. Drugs Exp Clin Res. 1989;15 (6-7) :273-89.